ANI Pharmaceuticals Projects Over \$1 Billion in 2026 Revenue, Accelerating Rare Disease Transformation

Key Highlights

• ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) expects total net revenue for 2026 to exceed \$1 billion, driven primarily by its Rare Disease segment, which is projected to represent approximately 60% of total revenues.
• The company forecasts a 23% year-over-year revenue increase in 2026 following a substantial 44% YoY revenue jump in 2025.
• Cortrophin Gel, ANI’s flagship rare disease product, is expected to generate \$540-575 million in revenue in 2026, reflecting a 55-65% YoY growth and accounting for the majority of the Rare Disease segment’s performance.
• The Generics business continues to deliver strong cash flows, enabling further investment in the Rare Disease pipeline and maintaining operational excellence with a diversified portfolio and robust U.S. manufacturing footprint.
• ANI provided updated 2026 guidance:
  • Net Revenue: \$1,055–\$1,115 million
  • Adjusted Non-GAAP EBITDA: \$275–\$290 million (20–26% YoY growth)
  • Adjusted Non-GAAP Diluted EPS: \$8.83–\$9.34 (12–18% YoY growth)
  • Adjusted non-GAAP gross margin: 59.3%–60.3%
  • Blended royalty rate due to Merck for Cortrophin Gel: high-20 percent range
• ANI is deploying a new 90-person organization to target the acute gouty arthritis market and is advancing a Phase 4 trial for Cortrophin Gel, positioning it for further multi-year growth.
• The company completed the acquisition of Alimera in September 2024, adding ILUVIEN to its portfolio and expanding its Rare Disease business in ophthalmology.
• Year-end 2025 cash was reported at \$286 million with net leverage of approximately 1.5x, indicating strong financial flexibility for continued investment and growth.

Details and Potential Share Price Drivers

• Rare Disease Business as Growth Engine:
  • ANI’s strategic focus on Rare Disease, particularly with Cortrophin Gel and ILUVIEN, underpins its transformation into a leading biopharma in this space.
  • Cortrophin Gel’s net revenue saw an 84% YoY growth in 2025 and is expected to grow by another 60% in 2026, signifying rapid adoption and market penetration across multiple specialty indications, including nephrology, neurology, rheumatology, ophthalmology, and pulmonology.
  • The launch of a dedicated sales force for acute gouty arthritis and investment in clinical evidence (Phase 4 trials) are designed to further increase market share and drive multi-year durable growth.
• Generics Segment Remains Robust:
  • The Generics division achieved 28% YoY topline growth in 2025, with revenues of \$384 million, and continues to fund innovation and expansion in the Rare Disease segment.
  • ANI maintains a disciplined R&D investment (high single-digit % of Generics revenue) and expects 10–15 new product launches annually, supporting future cash flow stability.
  • The company’s U.S.-centric manufacturing footprint (93% of finished goods revenue) insulates it from global supply chain disruptions and minimizes direct reliance on China (only ~5% of revenues).
• Integration of Alimera and ILUVIEN:
  • The 2024 acquisition of Alimera adds ILUVIEN, a long-acting ocular therapy for diabetic macular edema (DME) and chronic non-infectious uveitis affecting the posterior segment (NIU-PS), to ANI’s Rare Disease portfolio.
  • ILUVIEN contributed \$78–\$83 million in revenue in 2026 guidance, with strategic investments in marketing and medical affairs to drive further growth and awareness.
• Financial Strength and Capital Allocation:
  • ANI ended 2025 with \$286 million in cash and a net leverage ratio of 1.5x, providing ample flexibility for continued R&D investment, business development, and potential M&A.
  • The company’s disciplined capital allocation strategy includes ongoing investment in high-ROI commercial and clinical initiatives, especially for Cortrophin Gel.
• Shareholder-Relevant Information and Price Sensitivity:
  • ANI’s guidance for >\$1 billion in revenue, 23% YoY growth, and rapid expansion in its Rare Disease segment are highly positive and could be significant catalysts for share price appreciation.
  • The market may react strongly to the rapid growth of Cortrophin Gel, the successful integration of ILUVIEN, and the company’s ability to generate cash flow from its Generics business to fund innovation and further expansion.
  • Any deviation from these growth trajectories, adverse outcomes in clinical trials, or unexpected regulatory challenges could pose risks to valuation.

Strategic Priorities for 2026

• Accelerate transformation into a leading Rare Disease company
• Continue excellence in Generics R&D and operations
• Execute disciplined capital allocation strategy
• Drive high return on investment from new commercial and clinical initiatives (e.g., new gout-focused team, Phase 4 Cortrophin Gel trial)

Conclusion

ANI Pharmaceuticals’ 2026 outlook signals a company in the midst of a transformation, with Rare Disease products at the core of its growth story. The company’s impressive financial guidance, strong cash position, and execution of strategic initiatives—especially in Cortrophin Gel and the integration of ILUVIEN—are all highly relevant to investors and have the potential to move share prices materially. Shareholders should monitor execution against these ambitious targets, competitive dynamics in the Rare Disease and Generics markets, and progress on clinical and commercial milestones.

Disclaimer: The above article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions.

View ANI PHARMACEUTICALS INC Historical chart here